Search
Prolyl 4-hydroxylase
go.drugbank.com/bio_entities/BE0009980EnzymeHumansCatalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins … Catalyzes the post-translational formation of 4-hydroxyproline in -Xaa-Pro-Gly- sequences in collagens and other proteins
Polypeptides: Prolyl 4-hydroxylase subunit alpha-1, Prolyl 4-hydroxylase subunit alpha-2Synonyms: 4-PH alpha-1, 4-PH alpha-2Fosgemcitabine palabenamide
go.drugbank.com/drugs/DB15057InvestigationalNUC-1031 is under investigation in clinical trial NCT03610100 (Acelarin First Line Randomised Pancreatic Study).
Categories: Heterocyclic Compounds, 1-RingSynonyms: BENZYL (2S)-2-((((2R,3R,5R)-5-(4-AMINO-2-OXO-PYRIMIDIN-1-YL)-4,4-DIFLUORO-3-HYDROXY-TETRAHYDROFURAN-2-YL)METHOXY-PHENOXY-PHOSPHORYL)AMINO)PROPANOATE, L-Alanine, N-[[P(S)]-2'-deoxy-2',2'-difluoro-P-phenyl-5'-cytidylyl]-, phenylmethyl esterN-acetylglucosamine-6-phosphate deacetylase
go.drugbank.com/bio_entities/BE0001686TargetBacillus subtilis (strain 168)Catalyzes the hydrolysis of the N-acetyl group of N-acetylglucosamine-6-phosphate (GlcNAc-6-P) to yield glucosamine 6-phosphate and acetate (PubMed:14557261).
Polypeptides: N-acetylglucosamine-6-phosphate deacetylaseSynonyms: GlcNAc 6-P deacetylaseInterleukin-6 receptor subunit alpha
go.drugbank.com/bio_entities/BE0002859TargetHumansPart of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal (PubMed:28265003). Signal activation necessitate an association with IL6ST.
Polypeptides: Interleukin-6 receptor subunit alphaSynonyms: IL-6 receptor subunit alphaProteasome subunit alpha type-6
go.drugbank.com/bio_entities/BE0003915TargetHumansComponent of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associat...
Polypeptides: Proteasome subunit alpha type-6Glucose-6-phosphate exchanger SLC37A4
go.drugbank.com/bio_entities/BE0011751TargetHumansInorganic phosphate and glucose-6-phosphate antiporter of the endoplasmic reticulum (PubMed:10026167, PubMed:21949678). … Transports cytoplasmic glucose-6-phosphate into the lumen of the endoplasmic reticulum and translocates inorganic phosphate into the opposite direction (PubMed:41136424, PubMed:41225049, PubMed:33964207
Polypeptides: Glucose-6-phosphate exchanger SLC37A4Synonyms: Solute carrier family 37 member 4, Glucose-6-phosphate translocaseFulvestrant
go.drugbank.com/drugs/DB00947ApprovedInvestigationalFulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. … While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with [alpelisib] for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: (7α,17β)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1(10),2,4-triene-3,17-diolPutative 4-hydroxy-4-methyl-2-oxoglutarate aldolase
go.drugbank.com/bio_entities/BE0001689TargetMycobacterium tuberculosisCatalyzes the aldol cleavage of 4-hydroxy-4-methyl-2-oxoglutarate (HMG) into 2 molecules of pyruvate.
Polypeptides: Putative 4-hydroxy-4-methyl-2-oxoglutarate aldolaseFunction: 4-hydroxy-4-methyl-2-oxoglutarate aldolase activityBendamustine
go.drugbank.com/drugs/DB06769ApprovedInvestigationalBendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). … Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: PURPULZ ® 180 MG/4 ML, XEBINA® 25 MGFingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalMultiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. … It was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesProducts: FINGOLIMOD SUN, LEBRINA® 0.5 MG